Pyridinylimidazoles as dual glycogen synthase kinase 3 beta/p38 alpha mitogen-activated protein kinase inhibitors

Heider, Fabian and Ansideri, Francesco and Tesch, Roberta and Pantsar, Tatu and Haun, Urs and Doering, Eva and Kudolo, Mark and Poso, Antti and Albrecht, Wolfgang and Laufer, Stefan A. and Koch, Pierre (2019) Pyridinylimidazoles as dual glycogen synthase kinase 3 beta/p38 alpha mitogen-activated protein kinase inhibitors. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 175. pp. 309-329. ISSN 0223-5234, 1768-3254

Full text not available from this repository. (Request a copy)

Abstract

Compounds simultaneously inhibiting two targets that are involved in the progression of the same complex disease may exhibit additive or even synergistic therapeutic effects. Here we unveil 2,4,5-trisubstituted imidazoles as dual inhibitors of p38 alpha mitogen-activated protein kinase and glycogen synthase kinase 3 beta (GSK3 beta). Both enzymes are potential therapeutic targets for neurodegenerative disorders, like Alzheimer's disease. A set of 39 compounds was synthesized and evaluated in kinase activity assays for their ability to inhibit both target kinases. Among the synthesized compounds, potent dual-target-directed inhibitors showing IC50 values down to the low double-digit nanomolar range, were identified. One of the best balanced dual inhibitors presented in here is N-(4-(2-ethyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide (20c) (p38 alpha, IC50 = 16 nM; GSK3 beta, IC50 = 35 nM) featuring an excellent metabolic stability and an appreciable isoform selectivity over the closely related GSK3 alpha. Our findings were rationalized by computational docking studies based on previously published X-ray structures. (C) 2019 Elsevier Masson SAS. All rights reserved.

Item Type: Article
Uncontrolled Keywords: CYTOKINE UP-REGULATION; P38 MAP KINASE; SYNAPTIC DYSFUNCTION; P38-ALPHA MAPK; IMIDAZOLES; IDENTIFICATION; OPTIMIZATION; PREDICTION; MOLECULES; ASSAY; Kinase inhibitors; Pyridinylimidazoles; Glycogen synthase kinase 3 beta; p38 alpha MAP kinase; Dual inhibitors; Alzheimer's disease
Subjects: 500 Science > 540 Chemistry & allied sciences
600 Technology > 615 Pharmacy
Divisions: Chemistry and Pharmacy > Institute of Pharmacy
Chemistry and Pharmacy > Institute of Pharmacy > Pharmaceutical/Medicinal Chemistry II (Prof. Buschauer)
Depositing User: Dr. Gernot Deinzer
Date Deposited: 02 Apr 2020 07:56
Last Modified: 02 Apr 2020 07:56
URI: https://pred.uni-regensburg.de/id/eprint/26587

Actions (login required)

View Item View Item